Clinical trials: Neck Lines
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic…
- Trial name
- NCT05798819
- Testing
- GLS-010, paclitaxel, cisplatin
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Nasopharyngeal Carcinoma
The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is the most common malignant tumor of head and neck in southern China. After standard treatment, about 20% of the patients had local recurrence or distant metastasis, and the patients faced death in a…
- Trial name
- NCT04917770
- Testing
- Sintilimab in combination with Multimodality Radiotherapy
- Volunteers
- 28 people
- Sponsor
- West China Hospital
Esophageal Carcinoma
Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma
The purpose of this study is to evaluate the safety, tolerance and efficacy of Liposomal Paclitaxel With Nedaplatin as First-line in patients with Advanced or Recurrent Esophageal Carcinoma
- Trial name
- NCT02861690
- Testing
- Liposomal Paclitaxel, Nedaplatin
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Pancreas Cancer
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
This prospective, randomized, open-label and multicenter phase III study is aimed to estimate the survival benefit of Early Palliative Care (EPC) combined with standard oncology care including first-line chemotherapy…
- Conditions
- Gastric Cancer, Pancreas Cancer, Bile Duct Cancer, Gastroesophageal Cancer
- Trial name
- EPIC-1511 (NCT02853474)
- Testing
- Early Palliative Care visit, EORTC-QLQ-C30 questionnaire, HADS score
- Where
- 20 sites in France
- Volunteers
- 480 people
- Sponsor
- Centre Oscar Lambret
Head & Neck Squamous Cell Carcinoma
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
phase II, randomized, double-blind, placebo controlled, non pharmacological clinical trial that aims to determine the effect of postbiotics Postbiotix-HLA™ on immuno-related adverse events (irAEs) in patients with…
- Trial name
- POST-BIO (NCT07485296)
- Testing
- Postbiotix-HLA™ is a food supplement based on fermented FOS from Lactobacillus paracasei CNCM I-5220 postbiotic., Pembolizumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or
Chemotherapy for Patients With Cancer of the Stomach
The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.
- Trial name
- DOS (NCT01928524)
- Testing
- DOS2w Dose level 1A, DOS2w Dose level 2A, DOS2w Dose level 3A
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Per Pfeiffer
Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab…
- Trial name
- PEMBRO-PET (NCT07448727)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Rome Tor Vergata
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Esophageal Cancer
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab.
- Trial name
- NCT06718205
- Testing
- Nimotuzumab, Sintilimab, Paclitaxel-albumin
- Where
- China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Squamous Cell Carcinoma of Head and Neck
Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas
This is a phase II, prospective, non-randomized, single-arm, multicentric study to evaluate the activity and safety of treatment with 4 cycles (instead of 6) of chemotherapy (platinum (cisplatin or carboplatin) and…
- Trial name
- REDUCE (NCT06557889)
- Testing
- Pembrolizumab + Cisplatin/Carboplatin + 5-FU
- Where
- 13 sites in France
- Volunteers
- 86 people
- Sponsor
- Institut Claudius Regaud
Esophageal Neoplasms, Esophageal Diseases
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal…
- Conditions
- Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
- Trial name
- NCT05624099
- Testing
- camrelizumab, Paclitaxel drugs, Platinum drug
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fujian Cancer Hospital
Head and Neck Squamous Cell Carcinoma
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases.
- Trial name
- NCT07744126
- Testing
- Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 150 people
- Sponsor
- AbbVie
Head and Neck Cancer
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
This is an open-label phase II, multicenter study. Eligible patients will receive CP-751,871 in monotherapy (20 mg/kg IV infusion on Day 1 of 3-week cycles). Tumor check-up will be performed every 6-8 weeks.
- Trial name
- NCT00872404
- Testing
- CP-751,871
- Where
- 2 sites in Belgium
- Volunteers
- 37 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cervical Cancer
Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
- Trial name
- NCT03546855
- Testing
- Apatinib
- Volunteers
- 69 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Carcinoma
Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
The purpose of this study is to test the drug bevacizumab in combination with cetuximab. Because this combination has not been tested in cancer patients before, results will be analyzed to see what effects the combination of…
- Trial name
- NCT00636298
- Testing
- Bevacizumab, cetuximab
- Sponsor
- Emory University
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable…
- Trial name
- NCT04220866
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Nasopharyngeal Neoplasms
Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma
Primary: To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse.
- Trial name
- NCT00363831
- Testing
- Oxaliplatin
- Where
- Hong Kong
- Volunteers
- 42 people
- Sponsor
- The University of Hong Kong
Cancer of the Tongue
Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL
In terms of incidence, cancer of the tongue is one of the leading cancers in France. Moreover, this cancer is associated with physiological complications ranging from swallowing disorders to loss of taste.
- Trial name
- NCT03305302
- Testing
- Sample of cancerous epithelium from the tongue
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT07791745
- Testing
- Enlituo® + Anyouping® + PBC
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd